Extensive SCLCDose intensityDespite significant advances in the treatment of small cell lung cancer (SCLC), complete response and survival rates have remained essentially stable, and a variety of strategies have been implemented in attempts to improve therapeutic impact. Increasing dose intensity, for ...
Extensive-stage small-cell lung cancer (ES-SCLC) is one of the most lethal malignancies, with a median overall survival of only 8-10 months with first-line chemotherapy despite response rates of 60%-80%. In the second-line setting, the prognosis is even more limited, with only 20%-30%...
The overall and disease-free survival rates were calculated based on the extent of disease. 19 cases were male and four female with the mean age of 58±9 years. The18F-FDG PET/CT identified limited and extensive diseases in 2 (8.7%) and 21 (91.3%) patients, respectively. In addition, ...
The CREST study showed that the addition of thoracic radiotherapy (TRT) could improve the survival rate in patients with extensive stage small cell lung cancer (ES-SCLC), but whether TRT can bring survival benefit in the era of immunotherapy remains controversial. This study aimed to explore the...
SCLC is one of the most aggressive and devastating solid tumor malignancies, with a median survival of approximately 12 months following initial therapy and a 3% five-year relative survival rate for ES-SCLC.1,6,7Current second-line...
(positivity rates of 8.8% and 44.1% respectively). HLA class II on TILs was negatively correlated with lymph node metastasis and associated with longer recurrence-free survival (RFS), underscoring the prognostic and clinical significance of HLA class II in SCLC patients [104]. A post-hoc ...
typically been treated with etoposide plus either carboplatin or cisplatin as standard first-line treatment. Despite initially high response rates to chemotherapy, most patients relapse within 6 months of completing treatment; prognosis for these patients is poor with a 2-year survival rate of < 5% ...
With linear regression analysis, we were unable to find a relationship between survival and dose per cycle of etoposide or cisplatin. Variations in the administration of this regimen had no impact on outcomes in patients with extensive SCLC. 展开 ...
SCLC is one of the most aggressive and devastating solid tumor malignancies, with a median survival of approximately 12 months following initial therapy and a 3% five-year relative survival rate for ES-SCLC.1,6,7Current ...
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths worldwide, with up to 14% being classified as SCLC in the U.S.1,2Most patients with SCLC are diagnosed with extensive-stage disease and have a 5-year survival r...